Impact of GOLD-adherent Versus GOLD- nonadherent Prescribing on All-cause HCRU GOLD-adherent prescribing was associated with significant reductions in proportions of patients with all-cause hospitalizations and ED visits compared with GOLD-nonadherent prescribing (OR, 0.69 and 0.63, respectively), although only 4% to 6% of patients in both groups experienced these events during the 180 days following index treatment (Figure 3). Compared with undertreatment, GOLD-adherent prescribing was associated with a significant reduction in all-cause hospitalizations and ED visits (OR, 0.64 [P=0.0105] and 0.66 [P=0.0249], respectively; Figure 4). Similarly, GOLD-adherent prescribing was accompanied by a significant decrease in all-cause ED visits compared with overtreatment (OR, 0.61; P=0.0042; Figure 4).